Gwendolyn Shipe
Psychiatry · Dallas, TXNPI 1922180322
Payments from drug & device makers
Across 166 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$944
- Otsuka America Pharmaceutical, Inc.$847
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$452
- Corium, LLC$416
- Axsome Therapeutics, Inc.$276
- AbbVie$238
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$50011%
- Food & beverage$4,09489%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,594 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $16,916 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $10,594 |
| DayvigoLemborexant | 24 | $7,935 |
| ViibrydVilazodone Hcl | 18 | $7,347 |
| Aripiprazole | 23 | $2,139 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $981 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $604 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $460 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 41 | $424 |
| Bupropion XlBupropion Hcl | 29 | $307 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $233 |
| Trazodone Hcl | 37 | $215 |
| Paroxetine Hcl | 11 | $148 |
| Lithium Carbonate ErLithium Carbonate | 18 | $139 |
| Clonazepam | 14 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $847 | $16,91612 claims |
| Eisai Inc.Dayvigo | $229 | $7,93524 claims |
| AbbVieViibryd | $238 | $7,34718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.